Posts Tagged ‘HCG’

ASX Company News: Helicon Group Acquires Aspen Medisys

Thursday, August 11th, 2011

Helicon Limited (HCG) is pleased to announce it has signed a letter of intent with Aspen Medisys LLC to acquire 100% of the issued capital of AML for an amount of AUD$1.5m in HCG scrip. The doom and gloom of the current market conditions in the US has favored Helicon in this acquisition of AML.

Rod Tomlinson, Chairman of HCG said: “Our CEO Fabio Pannuti recently stated that if we can monetize this technology within HCG, we will become a very large company. I am now sure that we have the basis to deliver on this. Our executive staff, combined with the world-class personnel expertise at AML, makes for an outstanding scientific and corporate team. Having now completed our technical due diligence I am convinced the scientific platform upon which AML is predicated is not only sound, but also unique and it works. I believe that we have negotiated an excellent deal in acquiring Aspen Medisys. Once we spend the development money on what needs to be done next and achieve a successful outcome, the end value of this asset, if I base it on comparable technologies, is in excess of AUD$200m. Our base cost is estimated, including the AUD$3.5m scrip acquisition payment, at AUD$6.5m. I would therefore anticipate that this would be favourably reflected in our market capitalization over the ensuing quarters.”

AML owns an exciting energized nanoparticle technology for the treatment of tumors that was co-developed with Aduro BioTech, Inc., a significant shareholder in AML and longstanding investor and scientific developer in this field. The types of tumors that may be treated by this nanotechnology include tumors associated with ovarian, lung and pancreatic cancers. AML’s patented technology enables very precise temperature increases to be targeted to diseased tissues using magnetically heated nanoparticles implanted in the diseased tissue. Helicon Group Limited was formed to license pharmaceuticals for sale in North Asia. It has extended the scope of its activities by acquiring the VibroveinTM and BreatheAssistTM products, which it will seek to license to pharmaceutical or medical device companies for a variety of indications and geographical segments.

www.helicongroup.com.au

http://www.traderdealer.com.au/fundamentals/hcg

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

ASX Company News: Helicon Group Acquires OzPharma’s Intellectual Property

Thursday, June 30th, 2011

Helicon Group Limited (HCG) announced that it has entered into an agreement to acquire all the Intellectual Property associated with OzPharma’s Buccal technology known as LINGUET. The Linguet is at the tail end of OzPharma’s multimillion-dollar development program and now reached a significant commercialisation milestone.

Fabio Pannuti, Helicon MD said, “We are particularly pleased to have acquired this technology on such favourable terms and look forward to working with the OzPharma team to complete the development of what is a very valuable asset.” Mr Pannuti went on to say, “We have now completed our restructuring of Helicon and put in place a strategy and a team capable of identifying, acquiring and building a drug delivery technology portfolio that will deliver shareholders strong returns over multiple licensing opportunities. The Linguet provides a valuable addition to this extraordinary portfolio.”

Under the terms of the agreement Helicon has the right to acquire the Linguet by paying OzPharma a consideration of: $50,000, 15% of Linguet royalties paid to Helicon, 1,370,000 Helicon shares and a call option over the new subsidiary company that Helicon will form to hold the technology. OzPharma are not able to exercise the Call Option until one month after two key Linguet patents have been granted in the USA. Helicon may terminate the Call Option prior to it being capable of being exercised by the payment to OzPharma of 25,000,000 ordinary Helicon Shares.

Helicon Group Limited was formed to license pharmaceuticals for sale in North Asia. It has extended the scope of its activities by acquiring the VibroveinTM and BreatheAssistTM products, which it will seek to globally license to pharmaceutical or medical device companies for a variety of indications and geographical segments.

www.helicongroup.com.au

http://www.traderdealer.com.au/fundamentals/hcg

Post to Twitter

Tags: , , ,
Posted in ASX Company News | No Comments

ASX Company News: Helicon Group Completes Stage 5 Testing Of Vibrovein

Wednesday, June 8th, 2011

Helicon Group Limited (HCG) is pleased to announce successful  completion of Stage  5 testing of its product Vibrovein™. Vibrovein is a unique electronic device designed to markedly increase clinician accuracy, reduce patient pain and improve drug delivery from syringes; of which at least  20 billion are used around the world annually.

Following the  recent acquisition by Helicon, the research program to validate the Vibrovein™ technology has been progressing to schedule and within budget.  The validation program  is a prelude to  proposed  licensing discussions  with multinational Pharmaceutical and Medical Device Companies intended to commence in CYQ4, 2011 to monetize the Vibrovein™ device.

The original penetration-force testing instrument rig has been brought to Australia from the  UK where  it was bench trialed at  Oxford. The instrument has been installed and calibrated at the Invetech Research Centre in Melbourne to expedite advanced testing and experimentation.   The test rig is ensuring the Vibrovein™ device configuration is optimized in various usage settings.    A further series of tests utilizing specialized photography was initiated to observe the clinical properties of the Vibrovein™ device in procedures involving human subjects.  This photography  has  afforded our Company  a significantly deeper understanding of the benefits of this technology.  The trials have generated a wealth of new information on the technical aspects of the Vibrovein™ device and confirmed the uniqueness of the scientific approach.  Further ultra high-speed photography testing will continue when all in-laboratoryand in-surgery data generated to date has been evaluated.

Dr. John Marx, the lead clinical investigator and inventor of the technology said today: “The test results that have arisen as a consequence of design change input from Invetech under Rod Tomlinson’s direction, were for me really quite exciting and impressive.   Rod’s recent enhancements to my original design concept have caused us to witness dramatic  improvements in  the device. Despite using my invention for almost 5 years in surgery and being satisfied as a clinician, I never foresaw such a  phenomenon. It is evident that working with  this distinguished team will translate to further outstanding results in the near future.  These in will certainly  be transferred to  improved  patient  adoption and  comfort, surgical efficacy and ultimately benefit Helicon and its shareholders”.

www.helicongroup.com

http://www.traderdealer.com.au/fundamentals/hcg

Post to Twitter

Tags: , , ,
Posted in ASX Company News | No Comments

ASX Company News: Helicon Group To Acquire Leading Edge Instruments

Wednesday, November 10th, 2010

Helicon Group Limited (HCG) is pleased to announce that it has executed a Heads of Agreement (HOA) with Leading Edge Instruments Ltd (LEI) to acquire up to 100% of the issued capital of LEI. LEI is an unlisted public company that controls two exciting, near-market medical device technologies, BreatheAssist® and Vibrovein® that have the potential to become major products.

The Vibrovein® technology is wholly owned by LEI and the BreatheAssist® technology is wholly owned by ASAP Breatheassist Pty Ltd (“ASAP”), a company LEI will acquire prior to the completion of this transaction.  BreatheAssist® is a nasal device that has broad medical and healthcare applications including improved breathing outcomes, sleep improvement, and as an innovative and potentially revolutionary nasal drug delivery device.

Vibrovein® is an adjunct device that can be attached to any needle with applications including reduced pain, ease of puncture and ease of use targeting a multi billion dollar market.  The LEI business strategy is based on a licensing model that removes direct manufacturing and marketing risk in exchange for a licensing fee. The company expects to spend a further $1.2 million on the development of these technologies to bring them to a stage ready for licensing to a global pharma or medical device group. Helicon has more than $2 million in cash reserves, sufficient for the merged group to reach licensing deals.

Dr Saliba Sassine, Chairman of Helicon commented “the Board of Helicon is delighted to announce this transaction which provides Helicon with the opportunity to generate significant revenue in two high potential market segments from Australian developed technologies.”

Rod Tomlinson, Executive Director of ASAP and Chairman of the LEI Scientific Committee commented “BreatheAssist® and Vibrovein® have exciting potential. Whilst they each offer suitable global licensees an opportunity in billion dollar plus markets, the risk factor of each is an order of magnitude lower than marketing a new drug molecule or vaccine”. Mr Tomlinson was formerly Chief Chemist at Smith and Nephew Australia and subsequent to that built and owned Soltec Research Pty Ltd. Soltec was the recipient of a number of awards including an Australian Small Business Award and an Australian Export Award.

www.helicongroup.com

http://www.traderdealer.com.au/Fundamentals/hcg

Post to Twitter

Tags: , , , ,
Posted in ASX Company News | No Comments

Helicon Group Share Purchase Plan

Tuesday, October 13th, 2009

Helicon Group (HCG) announced on the 12/10/2009 that they would be conducting a Share Purchase Plan to raise additional capital. The record date is the 20/10/2009 on which shareholders must own the share to participate in the SPP. The closing date is 27/11/2009.  Shares will be issued soon after.   A maximum of $15,000 can be purchased by each shareholder at $0.05 or a 20% discount to the volume weighted average price (VWAP).  The offer will be fully underwritten.

Discount : 9.6% Liquidity : Poor Profitability : Ok  Stability : Ok

www.helicongroup.com.au

* Note: Discount is based on the closing price on the 12 October 2009.

Post to Twitter

Tags: , , ,
Posted in Share Purchase Plan (SPP) | No Comments

Helicon Group Share Purchase Plan

Tuesday, October 13th, 2009

Helicon Group (HCG) announced on the 12/10/2009 that they would be conducting a Share Purchase Plan to raise additional capital. The record date is the 20/10/2009 on which shareholders must own the share to participate in the SPP. The closing date is 27/11/2009. Shares will be issued soon after. A maximum of $15,000 can be purchased by each shareholder at $0.05 or a 20% discount to the volume weighted average price (VWAP). The offer will be fully underwritten.

Discount : 9.6% Liquidity : Poor Profitability : Ok Stability : Ok

www.helicongroup.com.au

* Note: Discount is based on the closing price on the 12 October 2009.

For More Share Purchase Plans go to http://blog.mdsfinancial.com.au/category/share-purchase-plans/

To Buy Shares And Participate in Share Purchase Plans use Trader Dealer http://www.traderdealer.com.au/

Post to Twitter

Tags: , , ,
Posted in Share Purchase Plan (SPP) | No Comments